JAZZ - Jazz Pharmaceuticals plc Options
This article provides a detailed financial overview of Jazz Pharmaceuticals plc (JAZZ), including its last closing price, market capitalization, key financial ratios, EPS and sales growth rates, and various performance metrics. It also lists insider and institutional ownership, profitability margins, and technical indicators. The data presented covers stock performance over different periods, analyst recommendations, and target prices.
Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes
Jazz Pharmaceuticals (JAZZ) stock has broken out of a long-term trading base near an all-time high, driven by mixed news regarding its cancer drug Zepzelca and optimism surrounding Ziihera. Despite a 122.45% 1-year return, the company is considered 5.3% undervalued, with a fair value of $257.00. Investors are now evaluating if the recent surge leaves room for further upside, considering potential revenue streams from new therapies and ongoing investments in R&D and international launches.
Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes
Jazz Pharmaceuticals (JAZZ) stock has seen a significant breakout, with a 122.45% 1-year total shareholder return, despite mixed news regarding its cancer drug Zepzelca and optimistic expectations for Ziihera. The company is currently considered 5.3% undervalued, with a fair value of $257.00, driven by anticipated therapy approvals and international expansion. Investors are assessing whether the recent surge still offers upside given the P/E ratio of 16.3x versus the industry average of 33.7x, alongside potential risks like patent expiries and therapy uptake challenges.
Jazz Pharmaceuticals (JAZZ) CEO shares withheld to cover RSU tax obligations
Jazz Pharmaceuticals' President & CEO, Renee D. Gala, had 4,835 ordinary shares withheld on June 30, 2026, to cover tax obligations from vested restricted stock units. This was a tax-withholding disposition at $237.72 per share, not an open-market sale. Following this transaction, Gala directly holds 147,361 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals (JAZZ) insider RSU tax withholding detailed
Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena M. Patil, had 2,678 ordinary shares withheld on June 30, 2026, to cover tax obligations arising from the vesting of restricted stock units (RSUs). This transaction, valued at $637,000 based on a reference price of $237.72 per share, was a tax-withholding disposition and not an open-market sale. Following this, Patil directly holds 48,871 ordinary shares, an event common for equity compensation and not indicative of a discretionary trading decision.
Jazz Pharmaceuticals (JAZZ) EVP reports RSU tax withholding and retains 47,911 shares
Jazz Pharmaceuticals' EVP and Chief Commercial Officer, Samantha Pearce, reported a tax-related disposition of 2,527 ordinary shares at $237.72 per share to cover tax obligations arising from the vesting of restricted stock units. This was a non-market transaction for tax withholding purposes. After this transaction, Ms. Pearce directly holds 47,911 ordinary shares, and a separate footnote indicates she also acquired 166 shares through an employee stock purchase plan.
Jazz Pharmaceuticals (JAZZ) CFO reports 3,343-share tax withholding
Jazz Pharmaceuticals' EVP & CFO, Philip L. Johnson, reported a tax-withholding transaction where 3,343 ordinary shares were withheld at $237.72 per share to satisfy tax obligations on vesting restricted stock units. After this, he directly holds 56,431 shares. Additionally, Johnson acquired 166 ordinary shares through an employee stock purchase plan on May 29, 2026.
Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs?
Jazz Pharmaceuticals (JAZZ) has confirmed a bull flag breakout, with its stock closing above $243.32, reinforcing a long-term bullish trend. The stock's price activity indicates a higher swing low and successful test of the 50-day moving average, suggesting further upside potential if momentum holds. This development builds upon a major long-term base breakout that occurred in April, setting a strong structural foundation for continued growth.
Jazz Pharmaceuticals stock hits all-time high at 243.39 USD
Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $243.46, trading just below its 52-week high of $243.32, marking a 132% surge from its 52-week low. This strong performance, reflected in a 121.3% one-year change, is supported by the company's impressive 91.5% gross profit margin and strong cash flow, with analysts considering it undervalued. Despite a setback with its lung cancer drug Zepzelca not meeting primary endpoints in a Phase 3 trial, BofA Securities raised its price target for Jazz Pharmaceuticals, citing increased revenue growth from its Ziihera product.
Jazz Pharmaceuticals stock hits all-time high at 243.39 USD By Investing.com
Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $243.46, trading just below its 52-week high, marking a 132% surge from its 52-week low. Despite this impressive performance, InvestingPro analysis suggests the stock remains undervalued, highlighting a strong gross profit margin and cash flow. The company has also announced mixed news regarding its product pipeline, with a lung cancer drug failing to meet its primary endpoint in trials, but a narcolepsy treatment showing positive results and a price target increase from BofA Securities due to revenue growth from another product.
Bruce Cozadd files Form 144 to sell shares — Jazz Pharmaceuticals (NASDAQ: JAZZ)
Jazz Pharmaceuticals (NASDAQ: JAZZ) director Bruce Cozadd has filed a Form 144 to sell shares, detailing recent dispositions of 6,000 shares on three separate dates in 2026 (April 1, May 1, and June 1). The filing also shows previously issued stock options from 2018 and 2019. This administrative notice allows for the brokered resale of restricted or control securities by an affiliate.
Form 144 Jazz Pharmaceuticals Plc For: 1 July By Investing.com
This article announces the filing of Form 144 by Jazz Pharmaceuticals Plc for July 1. It is a brief financial news update from Investing.com. The content provided is primarily metadata and navigational information, indicating a simple notice of a regulatory filing.
Price to earnings forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ
This article provides financial data for Jazz Pharmaceuticals plc (NASDAQ: JAZZ), focusing on its forward price-to-earnings ratio. It indicates that the market is closed and no trades were made, with the period value and changes left blank. The content
Price to book forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ
This page provides financial data for Jazz Pharmaceuticals plc, specifically focusing on its price-to-book forward ratio. It highlights that the market was closed and no trades occurred, with the data being sourced from ICE Data Services, FactSet, and Quartr for SEC filings.
Enterprise value to revenue forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ
This article provides financial information for Jazz Pharmaceuticals plc (JAZZ) on the Nasdaq Stock Market. Specifically, it highlights the enterprise value to revenue forward metric for the company. The content appears to be a stub or a data point from a financial platform rather than a detailed analytical article.
Is Jazz Pharmaceuticals (JAZZ) Using AbCellera Deal to Quietly Redefine Its Oncology Strategy?
Jazz Pharmaceuticals recently entered a preclinical research collaboration with AbCellera Biologics to develop T-cell engaging multispecific antibodies for gastrointestinal and other solid tumors, with upfront payments totaling $84 million for three programs. This deal signals Jazz's strategy to expand its immuno-oncology pipeline and balance near-term oncology catalysts, like its Ziihera asset, with longer-term pipeline bets. The collaboration is an effort to broaden Jazz’s oncology base as the company faces looming patent expirations and pricing pressures on its oxybate products.
Is Jazz Pharmaceuticals (JAZZ) Using AbCellera Deal to Quietly Redefine Its Oncology Strategy?
Jazz Pharmaceuticals has entered a preclinical research collaboration with AbCellera Biologics to develop T-cell engaging multispecific antibodies for gastrointestinal cancers, involving upfront payments and significant milestone potential. This deal, aimed at expanding Jazz's immuno-oncology pipeline, comes as the company seeks to offset looming oxybate patent expirations by broadening its oncology and neuroscience portfolio. The article suggests this strategy balances near-term oncology catalysts like Ziihera expansion with longer-term pipeline investments, though investors must consider the impact of potential oxybate generic competition.
Price to sales forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ
This article from TradingView is a placeholder or an incomplete page focusing on the "Price to sales forward" metric for Jazz Pharmaceuticals plc (NASDAQ: JAZZ). It appears to be part of the financial data section for the company, but no actual numerical data or analysis is provided. The content mostly consists of navigation links, copyright information, and mentions of various TradingView features.
Erica Jefferson Joins Jazz Pharmaceuticals as Chief Communications Officer
Jazz Pharmaceuticals has appointed Erica Jefferson as its first Chief Communications Officer, unifying employee and external communications under her leadership. Reporting to CEO Renee Gala, Jefferson will lead the global communications strategy, aiming to strengthen Jazz's corporate reputation and stakeholder engagement. She brings over 20 years of experience in biopharmaceutical communications and government affairs, previously serving at the U.S. FDA and ReCode Therapeutics.
JAZZ Forecast — Price Target — Prediction for 2027
This article provides a forecast for Jazz Pharmaceuticals plc (JAZZ) stock, including analyst price targets, historical performance, and key financial metrics. It highlights the consensus price target from 18 analysts, the stock's recent price movements, and upcoming earnings information. The piece emphasizes that the content is not investment advice and encourages readers to conduct their own research.
Jazz Pharmaceuticals Public Limited Company Actuals & Estimates (NASDAQ:JAZZ)
This article provides an overview of Jazz Pharmaceuticals plc (JAZZ) stock, including its current price, historical performance, analyst forecasts, and financial details. It covers key metrics like market capitalization, earnings, revenue, and EBITDA, while also offering guidance on how to buy JAZZ stock and a general investment sentiment.
Jazz Pharmaceuticals (JAZZ) Reframed Zepzelca Growth, Is The Stock Still Below Fair Value?
Jazz Pharmaceuticals (JAZZ) is under investor scrutiny after reporting a phase 3 setback for its drug Zepzelca in one small cell lung cancer indication, while simultaneously highlighting its growth potential in another first-line maintenance indication. Despite a recent share price decline, the stock has shown strong returns over the past year and analysts suggest it is undervalued based on future revenue streams from new therapies. However, its P/S ratio is above peers, and patent pressure and competition pose potential risks to its long-term outlook.
Jazz Pharmaceuticals (JAZZ) Reframed Zepzelca Growth, Is The Stock Still Below Fair Value?
Jazz Pharmaceuticals (JAZZ) is under investor scrutiny after a mixed update on its cancer drug Zepzelca, with a Phase 3 setback in second-line small cell lung cancer but growth potential highlighted in its first-line maintenance indication. Despite recent share price fluctuations, the stock has shown strong long-term returns, leading to discussions about whether its current trading price below some fair value models represents an undervaluation or if future growth is already priced in. The company's pipeline and a new collaboration with AbCellera are key factors influencing its perceived value.
Strong Leaders Build Strong Teams - and Strong Teams Change Patients’ Lives - Jazz Pharmaceuticals
Jazz Pharmaceuticals emphasizes the critical role of strong leadership in building high-performing teams, which ultimately impacts patients' lives. The company highlighted a Pharmaceutical Executive feature on Rick Winningham, their lead independent board director and HBA's Honorable Mentor of the Year, praising his philosophy centered on developing mentees. Jazz Pharmaceuticals asserts that investing in people is as crucial as developing medicines, underscoring their commitment to human capital.
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration
Jazz Pharmaceuticals and AbCellera Biologics Inc. have entered a preclinical research collaboration to discover and develop T-cell multispecific antibodies targeting gastrointestinal cancers and other solid tumors. The agreement includes $56 million upfront for AbCellera and up to $792 million in potential milestone payments. Jazz will have the option to develop and commercialize the resulting therapeutic antibodies.
Will Zepzelca’s Failed LAGOON Trial in Second-Line SCLC Change Jazz Pharmaceuticals' (JAZZ) Narrative?
Jazz Pharmaceuticals' Zepzelca failed to meet its primary overall survival endpoint in the Phase 3 LAGOON trial for second-line metastatic small cell lung cancer, casting doubt on its role in this setting. While Zepzelca's first-line approval remains intact, this setback highlights the importance for Jazz Pharmaceuticals of diversifying its oncology pipeline and effectively launching other approved products to offset patent risks in its sleep franchise. Analysts may need to revise their optimistic revenue and earnings forecasts for Jazz given this trial result.
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback
Jazz Pharmaceuticals (JAZZ) stock has experienced a recent pullback, declining by 1.18% over 7 days and 1.14% over 30 days, despite strong longer-term momentum with a 1-year return of 109.65%. While analysts' consensus fair value of $225.53 suggests the stock is slightly overvalued, Simply Wall St's Discounted Cash Flow (DCF) model indicates a potential 73% undervaluation with an estimated future cash flow value of $836.86, presenting a significant discrepancy for investors to consider. The article highlights the ongoing debate between near-term analyst targets and long-term cash flow forecasts, coupled with risks like oxybate patent expirations.
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback
Jazz Pharmaceuticals (JAZZ) has experienced a recent pullback, with its stock declining over shorter periods, though showing strong momentum over the past year. While one fair value assessment suggests it is slightly overvalued by 1%, another view, based on a Discounted Cash Flow (DCF) model, indicates the stock could be trading about 73% below its estimated future cash flow value due to the recent price changes. The article encourages investors to analyze the underlying assumptions given the differing valuations and potential risks like patent expirations.
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
Jazz Pharmaceuticals (JAZZ) has announced a preclinical research collaboration with AbCellera Biologics (ABCL) to develop next-generation T-cell-engaging multispecific antibodies for GI cancers and other solid tumors. The partnership involves upfront payments of $56 million for the first two programs, with an additional $28 million for a third, and potential milestone payments and royalties for AbCellera reaching up to $792 million per program. This collaboration allows Jazz Pharmaceuticals to expand its oncology pipeline and leverage AbCellera's discovery platform, while AbCellera benefits from significant funding and validation of its technology.
Jazz Pharma announces late-stage trial setback for lung cancer therapy
Jazz Pharmaceuticals (JAZZ) announced that its late-stage trial for a small cell lung cancer therapy failed to meet its primary endpoint. The drug, lurbinectedin, when combined with irinotecan, did not improve overall survival in patients with advanced small cell lung cancer compared to the control arm. This news led to a more than 4% drop in the company's shares in premarket trading.
Jazz and AbCellera sign deal for T-cell engagers in solid tumours
Jazz Pharmaceuticals and AbCellera have partnered on a preclinical research, option, and licence agreement to discover and develop T-cell-engaging multispecific antibodies for gastrointestinal cancers and other solid tumours. The collaboration includes initial payments of up to $56 million to AbCellera, with potential additional payments and milestone fees totaling up to $792 million per program. AbCellera will handle discovery and early-stage research, leveraging its integrated platform for T-cell engagers.
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
Jazz Pharmaceuticals and AbCellera have announced a research collaboration to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. The agreement includes $56 million in upfront payments to AbCellera, with potential additional payments up to $792 million per program in option fees and milestone payments, plus tiered royalties on net sales. Jazz will have the exclusive right to develop and commercialize therapeutic antibodies resulting from the collaboration.
Insider Sell: Mark Smith Sells Shares of Jazz Pharmaceuticals PL
Mark Smith, a Director at Jazz Pharmaceuticals PLC, sold 1,157 shares of the company on June 15, 2026, reducing his ownership to 9,680 shares. This transaction is part of a broader trend, as there have been 27 insider sells and no buys at Jazz Pharmaceuticals over the past year. With shares trading at $230.55, the company is considered significantly overvalued based on its GF Value of $151.39.
Jazz Pharmaceuticals, AbCellera announce oncology deal
Jazz Pharmaceuticals and AbCellera have formed a research collaboration aimed at developing T-cell engaging multispecific antibodies for treating gastrointestinal cancers and other solid tumors. AbCellera is set to receive significant upfront payments and could earn up to $792 million per program in milestone payments. This partnership combines AbCellera's antibody discovery technology with Jazz Pharmaceuticals' focus on oncology and rare diseases.
Jazz, AbCellera line up $56M now and up to $792M per cancer program
Jazz Pharmaceuticals and AbCellera have entered into a preclinical research collaboration for next-generation T-cell engaging (TCE) multispecific antibodies targeting gastrointestinal cancers and other solid tumors. AbCellera will receive $56 million upfront for the first two programs and up to $792 million per program in potential option fees and milestone payments, plus tiered royalties, should Jazz exercise its options to develop and commercialize the antibodies. The partnership leverages AbCellera's antibody discovery engine to advance innovative treatments for difficult-to-treat cancers.
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
Jazz Pharmaceuticals and AbCellera have announced a preclinical research collaboration to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. The collaboration includes $56 million in upfront payments to AbCellera, with potential for up to $792 million in option and milestone payments per program. Jazz Pharmaceuticals will have the exclusive option to develop and commercialize therapeutic antibodies resulting from the collaboration.
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals announced 11 late-breaking presentations at SLEEP 2026, showcasing new research on Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for narcolepsy and idiopathic hypersomnia (IH). The data highlights the effectiveness of Xywav's individualized dosing and the cardiometabolic benefits of its low-sodium formulation. This research advances the understanding of these rare sleep disorders and the potential for Xywav to improve patient quality of life and long-term health outcomes.
[144] Jazz Pharmaceuticals plc SEC Filing
This article reports on a Form 144 SEC filing by Jazz Pharmaceuticals plc (JAZZ). The filing details the proposed sale of securities, including information about the filer, issuer, type of securities to be sold, and acquisition details. It specifies 1157 common shares to be sold with an aggregate market value of $266,746.35.
How Investors Are Reacting To Jazz (JAZZ) Zepzelca Failing Phase 3 LAGOON Survival Endpoint
Jazz Pharmaceuticals' Zepzelca recently failed its Phase 3 LAGOON trial for relapsed second-line metastatic small cell lung cancer, not improving overall survival. While this doesn't impact its existing first-line maintenance approval, it raises questions about its broader oncology role and highlights Jazz's reliance on a few key drugs. The company maintains its 2026 guidance, suggesting a reputational rather than immediate financial hit, but the setback challenges bullish revenue forecasts.
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
Jazz Pharmaceuticals' Zepzelca failed to meet its primary endpoint of overall survival in a phase III study for relapsed metastatic small cell lung cancer (SCLC), causing the company's shares to fall. While this is a setback for converting Zepzelca's accelerated approval to full approval in this indication, Jazz believes its previously issued 2026 financial outlook will not be impacted, largely due to Zepzelca's strong performance in the first-line maintenance SCLC setting. The company plans to discuss the study implications with the FDA.
Jazz Pharmaceuticals' Zepzelca misses primary goal in Phase 3 LAGOON trial
Jazz Pharmaceuticals announced that its Phase 3 LAGOON clinical trial for Zepzelca (lurbinectedin) in relapsed, second-line metastatic small cell lung cancer did not meet its primary endpoint of improving overall survival. Neither the monotherapy nor the combination arm with irinotecan showed a statistically significant survival advantage over standard chemotherapy. Despite this, Jazz stated that the result would not impact Zepzelca's existing commercial footprint or regulatory status, as its full FDA approval was based on a separate successful Phase 3 trial.
[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported an open-market sale of 1,200 ordinary shares for $231.83 each on June 10, 2026, totaling $278,196. This transaction was conducted automatically under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Patil directly holds 51,549 ordinary shares, in addition to acquiring 123 shares via an Employee Stock Purchase Plan on May 29, 2026.
Jazz Pharmaceuticals stock falls after lung cancer trial fails
Jazz Pharmaceuticals (NASDAQ:JAZZ) saw its stock fall after its Zepzelca drug failed to meet the primary endpoint of overall survival in a late-stage lung cancer trial (Phase 3 LAGOON). Despite this setback, no new safety signals were identified, and the company stated that the results do not impact Zepzelca's full U.S. approval in 2025, which is based on a separate Phase 3 trial. Jazz Pharmaceuticals has shared these results with the FDA and confirmed they do not affect its 2026 guidance.
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals announced that its Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) for relapsed metastatic small cell lung cancer (SCLC), did not meet its primary endpoint of overall survival. Despite this, the company emphasized that Zepzelca remains an important treatment, especially in the first-line maintenance setting in combination with immunotherapy, based on positive results from the earlier IMforte trial, which led to its full U.S. approval. The LAGOON results do not affect Zepzelca's existing approval for first-line maintenance and no new safety signals were identified.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Average Rating of "Moderate Buy" from Brokerages
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has received an average "Moderate Buy" rating from analysts, with 16 out of 19 recommending a buy and an average 12-month target price of approximately $246.06. The stock is currently trading near its 52-week high, and the company reported strong quarterly earnings and revenue. Recent insider selling by directors Bruce C. Cozadd and Heather Ann Mcsharry has been noted, while institutional ownership remains high at 89.14%.
Allianz Asset Management GmbH Boosts Stock Position in Jazz Pharmaceuticals PLC $JAZZ
Allianz Asset Management GmbH significantly increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 68.2% in the fourth quarter, reaching 598,832 shares valued at approximately $101.8 million. This move aligns with several analysts' upgrades and higher price targets for JAZZ, contributing to a "Moderate Buy" consensus rating and an average target price of $246.06. Despite some recent insider selling, institutional investors collectively own a substantial 89.14% of the company's shares.
[144] Jazz Pharmaceuticals plc SEC Filing
Jazz Pharmaceuticals plc (JAZZ) has filed a Form 144 Notice of Proposed Sale of Securities, detailing a broker-facilitated sale of 1,192 shares of Common Stock on May 28, 2026, for $282,468.24 by Neena Patil. The filing also reports 600 performance shares dated January 16, 2026, and 600 restricted shares dated March 5, 2025. This neutral filing suggests routine insider stock transactions without indicating positive or negative impact on the company.
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst
BofA Securities analyst Jason Gerberry reaffirmed a Buy rating for Jazz Pharmaceuticals (JAZZ) and raised the price target to $307, citing the firm's new cancer drug, Ziihera, as a significant revenue driver. A survey of oncologists indicated faster-than-expected adoption of the drug, leading to an estimated peak sales potential of $1.3 billion, a 30% increase from previous forecasts. This strong adoption and market opportunity are expected to fuel high-single-digit revenue growth for Jazz Pharmaceuticals between 2027 and 2032.
Jazz Pharmaceuticals plc Stock 12‑Month Price Target Raised to $259.28, Implies 13% Upside
Jazz Pharmaceuticals plc (JAZZ) has seen its average 12-month price target increased by analysts to $259.28, up from $257.83, with forecasts ranging from $229 to $307. This updated target suggests a 13% potential upside from its June 9 closing price. The consensus rating among 21 analysts remains a "Buy," with 18 recommending a Buy, 1 a Hold, and 2 a Sell.
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Xywav And Ziihera Updates And Strong Quarterly Results
Jazz Pharmaceuticals (JAZZ) has shown strong momentum recently due to updates on its sleep and oncology portfolios and better-than-expected quarterly results, leading to a significant increase in its share price. While analysts consider the stock slightly overvalued at $238.57 with a target of $225.53, a Discounted Cash Flow model suggests it could be significantly undervalued at $847.26, indicating a sharp disagreement in valuation perspectives. Investors are prompted to consider both the growth prospects and potential risks like patent expirations and execution challenges in oncology launches.
